

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM679327

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
DrugScan, Inc.		12/29/2020	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Frontida BioPharm, Inc.		
<b>Street Address:</b>	1100 Orthodox Street		
<b>City:</b>	Philadelphia		
<b>State/Country:</b>	PENNSYLVANIA		
<b>Postal Code:</b>	19124		
<b>Entity Type:</b>	Corporation: PENNSYLVANIA		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5073187	CAT.ONE	
<b>Registration Number:</b>	5025236	CAT.ONE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	3018960607		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2403304520		
<b>Email:</b>	uspto.filings@bw-iplaw.com		
<b>Correspondent Name:</b>	Joseph W. Berenato, III		
<b>Address Line 1:</b>	6550 Rock Spring Drive, Suite 240		
<b>Address Line 4:</b>	Bethesda, MARYLAND 20817		
<b>NAME OF SUBMITTER:</b>	Joseph W. Berenato, III		
<b>SIGNATURE:</b>	/jwb/		
<b>DATE SIGNED:</b>	10/06/2021		
<b>Total Attachments: 3</b>			
source=Drugscan to Frontida#page1.tif			
source=Drugscan to Frontida#page2.tif			
source=Drugscan to Frontida#page3.tif			

OP \$65.00 5073187

**ASSIGNMENT OF TRADEMARKS**

WHEREAS, DrugScan, Inc., a Delaware corporation, with an address of 200 Precision Drive, Horsham, Pennsylvania 19044 ("Assignor") has adopted, used and has been using the trademarks listed on Schedule A (the "Marks");

WHEREAS, Frontida BioPharm, Inc., a Pennsylvania corporation with an address of 1100 Orthodox Street, Philadelphia, PA 19124 ("Assignee") desires to obtain ownership of all rights in and to the Marks; and

WHEREAS, In connection with that certain Asset Purchase Agreement by and between Assignor and Assignee dated December 28, 2020, Assignor has agreed to assign and Assignee has agreed to acquire all of Assignor's rights in and to said Marks in the United States and the United States registrations thereof.

NOW THEREFORE in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:

Assignor does hereby assign unto Assignee all right, title and interest in and to the Marks in the United States, together with the goodwill of the business symbolized by the Marks, and the United States registrations thereof, including all rights in and to all causes of action, either in law or in equity for past, present, or future infringement based on the Marks.

Assignor agrees to execute all papers and to perform such other proper acts as Assignee may deem necessary to secure for Assignee or its designee the rights herein assigned.

DrugScan, Inc.  
Assignor

By: R Scott LaNeve

Name: R. Scott LaNeve

Title: General Manager, Drugscan

Date: December 29, 2020

Frontida BioPharm, Inc.  
Assignee

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Date: December 29, 2020

**ASSIGNMENT OF TRADEMARKS**

WHEREAS, DrugScan, Inc., a Delaware corporation, with an address of 200 Precision Drive, Horsham, Pennsylvania 19044 ("Assignor") has adopted, used and has been using the trademarks listed on Schedule A (the "Marks");

WHEREAS, Frontida BioPharm, Inc., a Pennsylvania corporation with an address of 1100 Orthodox Street, Philadelphia, PA 19124 ("Assignee") desires to obtain ownership of all rights in and to the Marks; and

WHEREAS, In connection with that certain Asset Purchase Agreement by and between Assignor and Assignee dated December 28, 2020, Assignor has agreed to assign and Assignee has agreed to acquire all of Assignor's rights in and to said Marks in the United States and the United States registrations thereof.

NOW THEREFORE in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:

Assignor does hereby assign unto Assignee all right, title and interest in and to the Marks in the United States, together with the goodwill of the business symbolized by the Marks, and the United States registrations thereof, including all rights in and to all causes of action, either in law or in equity for past, present, or future infringement based on the Marks.

Assignor agrees to execute all papers and to perform such other proper acts as Assignee may deem necessary to secure for Assignee or its designee the rights herein assigned.

DrugScan, Inc.  
Assignor

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Date: December 29, 2020

Frontida BioPharm, Inc.

Assignee

DocuSigned by:  
By: Ron Connolly  
B24728B364794B2...

Name: Ron Connolly

Title: Executive Vice President & Cofounder

Date: December 29, 2020

SCHEUDLUE A

<u>Trademark</u>	<u>Registration Number</u>	<u>Registration Date</u>
CAT.ONE	5,073,187	November 1, 2016
CAT.ONE	5,025,236	August 23, 2016